Exact Sciences' Shares Take a Hit Following Colorectal Cancer Dx Presentation

In results reported Thursday, the company said that its Cologuard test achieved of 64 percent sensitivity for pre-cancers and 85 percent for cancer and a specificity of 88 percent.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.